Seven Corners Issues Review of Allergan (AGN) Q2 and 1H 2017 Results, Reiterates Sell Rating, Sees 5

Seven Corners has published a writeup regarding Allergan's 2nd quarter and 1st half 2017 financial results, regarding which we note the following:

• Allergan’s non-GAAP financial metrics continue to mislead.

• In the writeup we review Allergan’s Q2 and 1H 2017 financial results.

• GAAP results highlight clearly declining operational performance.

• We reiterate our $117 target share price for Allergan.

To find a PDF containing our full AGN writeup, please visit our Research section (link here).